SCHEMBL2993136

SCHEMBL2993136

O=C(O)c1cccc(/C=C/C(=O)c2cccc(C(=O)O)c2)c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HB P07237 4/20 0.82
MAOB P27338 5/20 0.61
BCHE P06276 2/20 0.61
MAPT P10636 2/20 0.61
PLIN1 O60240 1/20 0.61
LMNA P02545 1/20 0.61
TNFRSF1A P19438 1/20 0.61
ACHE P22303 1/20 0.61
RECQL P46063 1/20 0.61
PLIN5 Q00G26 1/20 0.61
CYP1B1 Q16678 1/20 0.61
ABHD5 Q8WTS1 1/20 0.61
TTR P02766 3/20 0.60
UNG P13051 1/20 0.59
HDAC3 O15379 1/20 0.58
HDAC4 P56524 1/20 0.58
HDAC1 Q13547 1/20 0.58
HDAC7 Q8WUI4 1/20 0.58
HDAC2 Q92769 1/20 0.58
HDAC10 Q969S8 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2993138 1.00 P4HB (0.82) P4HBMAOBBCHEMAPTPLIN1
SCHEMBL7338954 0.93 P4HB (0.77) P4HBMAOBBCHEMAPTPLIN1
SCHEMBL31233485 0.93 P4HB (0.77) P4HBMAOBBCHEMAPTPLIN1
SCHEMBL7338947 0.93 P4HB (0.77) P4HBMAOBBCHEMAPTPLIN1
SCHEMBL30384014 0.91 P4HB (0.74) P4HBMAOBBCHEMAPTPLIN1
SCHEMBL2994069 0.91 P4HB (0.74) P4HBMAOBBCHEMAPTPLIN1
SCHEMBL2994067 0.91 P4HB (0.74) P4HBMAOBBCHEMAPTPLIN1
SCHEMBL13203405 0.87 CYP1B1 (0.81) P4HBMAOBBCHEMAPTPLIN1
SCHEMBL30383950 0.87 P4HB (0.78) P4HBMAOBBCHEMAPTPLIN1
SCHEMBL11452322 0.87 P4HB (0.78) P4HBMAOBBCHEMAPTPLIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7787085-B2 Optical alignment method and liquid crystal display element JSR CORPORATION (JP) 2010-08-31 US disclosed
US-7553809-B2 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2009-06-30 US disclosed
US-7553809-B2 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2009-06-30 US disclosed
US-7553809-B2 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2009-06-30 US disclosed
US-20080123046-A1 OPTICAL ALIGNMENT METHOD AND LIQUID CRYSTAL DISPLAY ELEMENT JSR CORPORATION (JP) 2008-05-29 US disclosed
US-20060057144-A1 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2006-03-16 US disclosed
US-20050259203-A1 Optical alignment method and liquid crystal display element JSR CORPORATION (JP) 2005-11-24 US disclosed
US-6835753-B2 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED (AU) 2004-12-28 US disclosed
EP-1109545-A4 Fc RECEPTOR MODULATORS AND USES THEREOF ILEXUS PTY LTD (AU) 2004-11-10 EP disclosed
EP-1353217-A1 Optical alignment method and liquid crystal display element JSR Corporation (JP) 2003-10-15 EP disclosed
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED 2002-05-23 US disclosed
US-6355683-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE ILEXUS PTY LIMITED (AU) 2002-03-12 US disclosed
EP-1109545-A1 Fc RECEPTOR MODULATORS AND USES THEREOF ILEXUS PTY LTD (AU) 2001-06-27 EP disclosed
US-6224788-B1 AROMATIC UNSATURATED KETONE POLYMERS JSR CORPORATION (JP) 2001-05-01 US disclosed
WO-2000015214-A1 Fc RECEPTOR MODULATORS AND USES THEREOF ILEXUS PTY LIMITED (US) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt FCGR2A, FCGR1A, FCER2 P4HB 2556/4885MAOB 1355/4885BCHE 2250/4885
US-20060057144-A1 Fc receptor modulators and uses thereof FCGR1A, FCER2, FCGR2A P4HB 2723/4885MAOB 1334/4885BCHE 1586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.